- ►annals.org [PDF] RG Hart, LA Pearce, MI Aguilar - Annals of Internal Medicine, 2007 - Am Coll Physicians Purpose: To characterize the efficacy and safety of antithrombotic agents for
stroke prevention in patients who have atrial fibrillation, adding 13 recent
randomized trials to a previous meta-analysis. Cited by 195 - Related articles - BL Direct - All 5 versions
- ►ua.edu [PDF] J Mant, FDR Hobbs, K Fletcher, A Roalfe, D … - The Lancet, 2007 - Elsevier 973 patients aged 75 years or over (mean age 81·5 years, SD 4·2) with atrial
fibrillation were recruited from primary care and randomly assigned to warfarin
(target international normalised ratio 2–3) or aspirin (75 mg per day). ... Cited by 127 - Related articles - All 30 versions
- ►ahajournals.org EM Hylek, C Evans-Molina, C Shea, LE … - Circulation, 2007 - Am Heart Assoc Methods and Results— Consecutive patients who started warfarin were identified
from January 2001 to June 2003 and followed for 1 year. Patients had to be 65
years of age, have established care at the study institution, and have ... Cited by 166 - Related articles - All 6 versions
- ►oxfordjournals.org A Rash, T Downes, R Portner, WW Yeo, N … - Age and ageing, 2007 - Br Geriatrics Soc Methods: randomised open labelled prospective study of primary
thromboprophylaxis for AF. Patients aged >80 and <90 were randomised to receive
dose-adjusted warfarin (INR 2.0–3.0) or aspirin 300 mg. All patients had ... Cited by 48 - Related articles - BL Direct - All 5 versions
FWA VERHEUQT, SJ CONNOLLY - Lancet(British edition), 2006 - cat.inist.fr Background Oral anticoagulation therapy reduces risk of vascular events in
patients with atrial fibrillation. However, long-term monitoring is necessary
and many patients cannot achieve optimum anticoagulation. We assessed ... Cited by 163 - Related articles - BL Direct - All 10 versions
- ►mkdocs.org [PDF] GC Flaker, M Gruber, SJ Connolly, S Goldman … - American heart journal, 2006 - Elsevier The 14% of patients receiving aspirin more often had diabetes (27.5% vs 23%, P <
.01), coronary artery disease (69% vs 41%, P < .01), previous stroke or
transient ischemic attack (26% vs 20%, P < .01), and left ventricular ... Cited by 50 - Related articles - All 8 versions
- ►ahajournals.org EM Hylek, J D'Antonio, C Evans-Molina, C … - Stroke, 2006 - Am Heart Assoc Background and Purpose— Numerous studies have documented under use of warfarin
particularly among elderly patients. A better understanding of the discrepancy
between trials and clinical practice will help inform stroke prevention ... Cited by 56 - Related articles - All 8 versions
- ►ahajournals.org BF Gage, C van Walraven, L Pearce, RG Hart, … - Circulation, 2004 - Am Heart Assoc From the Division of General Medical Sciences, Washington University School of
Medicine, St. Louis, Mo (BFG); Departments of Medicine and of Epidemiology and
Community Medicine, University of Ottawa, and Ottawa Health Research ... Cited by 241 - Related articles - BL Direct - All 7 versions
- ►biorankings.com [PDF] BF Gage, AD Waterman, W Shannon, M … - Jama, 2001 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context Patients who have ... Cited by 699 - Related articles - BL Direct - All 12 versions
M Results - Stroke, 2006 - Am Heart Assoc A spirin is still considered the standard treatment for secondary prevention of
stroke and other vascular events. Because several studies suggested that
triflusal (an antiplatelet agent structurally related to aspirin) may have ... Cited by 49 - Related articles - All 7 versions
